Stryker and CMR Surgical Announce Strategic Alliance

Stryker and CMR Surgical announced a strategic alliance, under which Stryker will make a strategic equity investment of approximately $400 million (£300 million), and receive an exclusive option to acquire all outstanding equity of CMR Surgical in the future, as well as an exclusive U.S. commercial agency agreement for the Versius portfolio. The agreement brings together CMR Surgical's globally established soft-tissue robotics portfolio, clinical experience and culture of innovation with Stryker's scale, deep customer relationships, commercial execution and proven track record of bringing innovative technologies to market. Stryker will serve as the exclusive U.S. sales agent for the Versius portfolio, while CMR Surgical will continue to lead portfolio development and commercialization in markets outside the United States. The alliance comes as demand for robotic-assisted surgery continues to grow, creating an opportunity to help healthcare providers expand robotic-assisted surgery programs with a scalable and practical solution. CMR Surgical's second-generation robot, with established clinical experience globally, supports a broad range of soft tissue procedures. Designed for real-world operating environments, the Versius platform's modular architecture supports flexibility across procedures, surgeon access and sites of care, and can help healthcare providers grow robotic adoption within existing operating room workflows. This information comes from the original source and was organized by AI.